Insmed Incorporated presents five abstracts featuring new respiratory data at the European Respiratory Society (ERS) Congress today, September 5, 2026, in Barcelona.
The company will highlight late-breaking Phase 3b ENCORE study data for ARIKAYCE in treatment-naive patients with Mycobacterium avium complex (MAC) lung infection.
Presentations include a post hoc analysis from the Phase 2 study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH).
Insmed will also share data from the Phase 3 ASPEN study of BRINSUPRI for non-cystic fibrosis bronchiectasis.